Innovative Genetic Testing Service 'Genovision PGx' Set to Transform Personalized Medicine
Transforming Personalized Medicine with Genovision PGx
In today's rapidly evolving medical landscape, the focus on personalized medicine has never been greater. NTT Precision Medicine has recognized this need and is set to launch a groundbreaking genetic testing service named 'Genovision PGx' in April 2026. This service will help predict individual responses to medication by analyzing genetic factors, aiming to ease concerns around drug efficiency and potential side effects.
Understanding the Need for Personalized Treatment
The rise of personalized medicine, also known as precision medicine, has made it crucial for healthcare providers to tailor treatments to each patient’s unique genetic makeup and health background. Many individuals experience varying degrees of effectiveness with the same medication, leading to a trial-and-error approach that can be both physically and financially taxing. Genovision PGx aims to mitigate these challenges by forecasting how patients might respond to different medications based on their genetic information.
PGx, which stands for pharmacogenomics, is gaining traction in Western countries as physicians and pharmacists increasingly leverage genetic insights to make informed treatment decisions. In response to this evolving trend, NTT Precision Medicine has developed Genovision PGx, designed to provide a proactive screening approach during health checkups, allowing individuals to understand their medication responsiveness well ahead of any treatment.
Service Overview
Reliable Genetic Analysis
Utilizing sophisticated analysis technology developed over years by the RIKEN institute, Genovision PGx examines 18 genes associated with drug responses. This scientific reliability ensures that the test results are relevant and beneficial for the Japanese population.
User-Friendly Reporting
The results from the analysis will be presented in an accessible report format based on the Japanese Consortium for Pharmacogenomics Implementation in Clinical Practice (JCPIC) guidelines. It includes two main components:
- - Efficacy trends for various medications
- - Side effect likelihood based on genetic predispositions
A One-Time Test for Lifelong Benefits
Genovision PGx will be offered as an optional check-up test at approximately 60 medical facilities across the country. Unlike many medical tests that require repeated analyses, genetic information remains consistent throughout a person's life. Hence, the results from a single test can influence future treatments, offering patients peace of mind by allowing them to discuss their genetic profiles with healthcare providers as needed.
Security and Privacy
Given the sensitive nature of genetic data, NTT Precision Medicine adheres to stringent security standards set by the NTT Group. The management and operation of genetic data strictly take place within Japan, prioritizing the privacy and safety of participants involved in the testing process.
For detailed information about the service, visit Genovision PGx.
Future Prospects
Looking ahead, NTT Precision Medicine aims to establish Genovision PGx within health screenings and ultimately validate its clinical value through cost-effectiveness analysis. The company also envisions seamless integration with electronic medical records and prescription logs, enabling patients to make data-driven decisions regarding their treatment for years to come.
In partnership with healthcare providers, NTT Precision Medicine strives to promote a future where, as they put it, “Drugs should be selected based on genetic information,” making personalized medicine the new standard in patient care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.